RDY Dr. Reddy's Laboratories Ltd

$-0.39 (-0.58%)

RDY Stock Analysis Overview

What this means: Dr. Reddy's Laboratories Ltd (RDY) gets an Overall Rank of 62, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. RDY's 62 means that it ranks higher than 62% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Dr. Reddy's Laboratories Ltd (RDY) Analyst Forecast

Next 12 months ➝No Forecast Data Available for RDYCurrent Price$66.9052-week High$73.5052-week Low$33.33
  • Last Price$66.90
  • Previous Close$67.29
  • Change $-0.39
  • Open$66.64
  • Volume203,073
  • Avg. Volume (100-day)176,345
  • Market Capitalization$11B
  • Days Range $66.28 - $67.20
  • 52-week Range $33.33 - $73.50
  • Dividend Yield0.50%
  • Ex. Dividend Date07/10/2020
  • P-E46
  • EPS1.61
  • Earnings Date10/28/2020
  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • Avg. Analyst Rec.
  • Beta0.658
  • PEG Ratio
With headquarters in India, Dr. Reddy's Laboratories develops and manufactures generic pharmaceuticals. The firm operates in three divisions: global generics, pharmaceutical services and active ingredients, and proprietary products and other, which make up most of the company's revenue at about 80%, 15%, and 3%. Most of the company's sales are based in the United States.